Grogan Jane 4

What Happened Jane Grogan, Head of Research at Biogen (BIIB), had restricted stock units (RSUs) convert into common shares on 2026-02-06. A total of 3,258 shares were acquired on conversion (1,385 + 1,873). To cover tax withholding liabilities, 991 shares (407 + 584) were surrendered/withheld at $201.18 per share, producing approximately $199,369 in withholding proceeds. The net new shares added to her holding from this event were 2,267 shares (3,258 acquired less 991 withheld). These were vesting/conversion transactions (not an open-market purchase or voluntary sale).

Key Details

• Transaction date: 2026-02-06; Form 4 filed 2026-02-10 (filed within the standard 2-business-day window).
• Conversions (code M): 1,385 and 1,873 RSU shares converted to common stock (total 3,258).
• Withholding/tax payment (code F): 407 and 584 shares withheld at $201.18 each, totaling $81,880 and $117,489 respectively (combined ~$199,369).
• Net shares retained from the conversion: 2,267 shares.
• Footnotes: F1 and F2 indicate these RSUs vest in three equal annual installments (grants dated 02/07/2024 and 02/06/2025 respectively).
• Shares owned following the transactions are not specified in the filing.

Context These entries reflect routine vesting and tax-withholding on equity awards rather than an open-market buy or sale. Code M indicates conversion/exercise of a derivative (here, RSUs converting to shares); code F indicates shares were surrendered/withheld to satisfy tax obligations (a common, administrative step). Such transactions typically do not by themselves signal a change in insider sentiment.